Accidental intoxications in toddlers: lack of cross-reactivity of vilazodone and its urinary metabolite M17 with drug of abuse screening immunoassays

Table 1 2D Similarity of Vilazodone and its Metabolites to Target Molecules of Drug of Abuse Immunoassays¹

	Vilazodone	M10 metabolite	M17 metabolite	M13 (6-Hydroxyvilazodone)	Lowest 2D similarity of cross-reactive compound (previous studies)
Amphetamines
Amphetamine	0.18	0.17	0.24	0.16	mCPP, TFMPP (0.23)²
Methamphetamine	0.16	0.16	0.23	0.14	mCPP, TFMPP (0.22) ²
MDMA/ecstasy	0.33	0.38	0.37	0.35	mCPP, TFMPP (0.25) ²
Barbiturates
Secobarbital	0.39	0.36	0.28	0.42	p-Hydroxyphenobarbital (0.72)
Benzodiazepines
Nordiazepam	0.44	0.37	0.33	0.43	α-Hydroxytriazolam (0.52)
Oxazepam	0.44	0.41	0.36	0.46	Alprazolam (0.47)
Cannabinoids
Δ⁹-THC-COOH	0.25	0.29	0.27	0.30	Cannabinol (0.80)
Cocaine metabolites Benzoylecgonine	0.41	0.50	0.34	0.46	Cocaethylene (0.85)
Opiates
Morphine	0.50	0.57	0.30	0.57	Rifampin (0.59)
Oxycodone	0.51	0.55	0.34	0.57	Noroxycodone (0.79)
Phencyclidine	0.46	0.46	0.22	0.41	Dextromethorphan (0.57)
Synthetic opioids
Buprenorphine	0.50	0.57	0.33	0.58	Buprenorphine glucuronide (0.78)
Methadone	0.31	0.31	0.31	0.28	Methadol (0.86)
Tricyclic compounds
Desipramine	0.45	0.45	0.33	0.42	Carbamazepine epoxide (0.40)
Imipramine	0.43	0.44	0.27	0.41	Carbamazepine epoxide (0.38)

¹ Values in bold are cases where the 2D similarity is higher than a known cross-reactive compound reported in an assay package insert or published literature
² Abbreviations: mCPP, Meta-chlorophenylpiperazine; TFMPP, Trifluoromethylphenylpiperazine

ISSN: 1472-6890